

FINANCIAL TRENDING SCHEDULES

FINANCIAL INFORMATION PRESENTED

- ▶ Balance Sheets Trend
 - Net Total Debt (Non-GAAP reconciliation)
 - Leverage ratio (Non-GAAP reconciliation)
 - Other debt-related ratios and rates
- ▶ Statements of Operations Trend
 - Adjusted Operating Income (Non-GAAP reconciliation)
 - Adjusted Net Income (Non-GAAP reconciliation)
 - Adjusted EPS (Non-GAAP reconciliation)
 - EBITDA (Non-GAAP reconciliation)
 - Adjusted EBITDA (Non-GAAP reconciliation)
 - Adjusted Interest Expense (Non-GAAP reconciliation)
 - Adjusted Effective Tax Rate (Non-GAAP reconciliation)
- ▶ Statements of Cash Flows Trend
 - Free Cash Flow (Non-GAAP reconciliation)
- ▶ Sales Trend
 - Organic Sales Change (Non-GAAP reconciliation)

NOTES

- Basis of Presentation
- Period end dates
- Non-GAAP Financial Information

Balance Sheets Trend

(\$ in thousands, except per share data; unaudited)



	2023				2024				2025			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Balance Sheets (GAAP)												
ASSETS												
Current assets:												
Cash and cash equivalents	\$ 40,604	\$ 38,615	\$ 32,142	\$ 23,674	\$ 42,156	\$ 34,137	\$ 35,574	\$ 46,543	\$ 31,711	\$ 23,135	\$ 58,944	\$ 17,161
Accounts receivable, net	250,513	236,526	226,327	231,283	237,154	240,504	241,708	245,269	276,235	302,262	310,165	346,079
Inventories	225,282	228,931	232,158	229,102	262,869	272,335	265,415	247,126	260,103	266,437	263,538	253,739
Contract assets	80,929	80,010	86,637	85,871	90,873	97,212	99,287	103,772	102,930	103,224	107,106	112,546
Prepaid expenses and other current assets	31,661	31,846	32,080	30,033	35,521	32,792	33,172	28,409	31,224	42,372	38,369	40,572
Current assets of discontinued operations held for sale	-	-	-	17,705	-	-	54,876	-	-	-	-	-
Total current assets	628,989	615,928	609,344	617,668	668,573	676,980	730,032	671,119	702,203	737,430	778,122	770,097
Property, plant and equipment, net (PP&E)	330,995	348,895	364,283	392,569	448,712	466,296	472,315	465,798	495,963	511,784	517,003	536,427
Goodwill	986,906	985,982	979,886	994,007	1,043,876	1,042,183	1,033,078	1,017,729	1,082,385	1,100,371	1,098,818	1,110,908
Other intangible assets, net	811,460	797,594	779,115	779,598	828,854	813,727	805,174	778,286	856,208	854,545	837,698	825,435
Deferred income taxes	6,363	6,447	6,398	7,001	7,026	6,858	6,782	8,309	8,370	8,517	8,545	8,994
Operating lease assets	72,532	70,281	67,418	81,319	83,243	81,345	78,624	86,082	99,147	100,912	99,514	98,437
Financing lease assets	8,650	8,537	8,352	11,675	12,630	16,549	17,205	27,689	29,928	31,717	32,151	37,109
Other long-term assets	27,655	27,680	24,553	22,407	23,095	22,474	24,439	22,959	23,499	25,659	25,459	23,170
Noncurrent assets of discontinued operations held for sale	-	-	-	36,409	-	-	-	-	-	-	-	-
Total assets	\$ 2,873,550	\$ 2,861,344	\$ 2,839,349	\$ 2,942,653	\$ 3,116,009	\$ 3,126,412	\$ 3,167,649	\$ 3,077,971	\$ 3,297,703	\$ 3,370,935	\$ 3,397,310	\$ 3,410,577
LIABILITIES AND STOCKHOLDERS' EQUITY												
Current liabilities:												
Current portion of long-term debt	\$ 10,000	\$ 5,000	\$ -	\$ -	\$ -	\$ -	\$ 5,000	\$ 10,000	\$ 11	\$ -	\$ -	\$ -
Accounts payable	124,280	107,507	108,351	118,258	116,220	119,446	116,837	101,498	112,023	117,367	110,744	113,130
Operating lease liabilities	10,222	10,075	9,977	8,564	8,550	8,729	8,883	7,352	8,708	8,922	9,125	9,099
Accrued expenses and other current liabilities	80,973	77,250	84,773	90,644	76,659	77,816	86,709	108,323	85,661	89,741	89,952	109,812
Current liabilities of discontinued operations held for sale	-	-	-	3,503	-	-	4,969	-	-	-	-	-
Total current liabilities	225,475	199,832	203,101	220,969	201,429	205,991	222,398	227,173	206,403	216,030	209,821	232,041
Long-term debt	992,469	980,398	941,383	959,925	1,140,724	1,118,529	1,074,339	980,153	1,235,204	1,202,495	1,193,826	1,185,179
Deferred income taxes	153,028	152,926	151,386	143,552	145,199	144,101	143,236	124,608	111,201	114,735	114,696	116,327
Operating lease liabilities	61,975	59,988	57,325	72,126	74,294	71,935	69,115	77,702	85,688	83,897	82,693	81,899
Financing lease liabilities	7,809	7,677	7,488	10,272	10,928	13,491	13,996	23,760	24,998	25,796	25,510	28,578
Other long-term liabilities	14,858	14,868	15,317	14,303	18,424	18,455	23,379	25,360	27,505	24,445	24,927	19,910
Noncurrent liabilities of discontinued operations held for sale	-	-	-	2,464	-	-	-	-	-	-	-	-
Total liabilities	1,455,614	1,415,689	1,376,000	1,423,611	1,590,998	1,572,502	1,546,463	1,458,756	1,690,999	1,667,398	1,651,473	1,663,934

Balance Sheets Trend

(\$ in thousands, except per share data; unaudited)



	2023				2024				2025			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Stockholders' equity:												
Common stock	33	33	33	33	34	34	34	34	35	35	35	35
Additional paid-in capital	709,171	715,715	721,283	727,435	725,247	730,157	736,125	741,977	754,021	760,741	765,566	771,223
Treasury stock	-	-	-	-	-	-	-	-	(26,858)	(26,858)	(26,858)	(76,872)
Retained earnings	693,766	717,737	744,994	771,351	791,859	823,105	858,544	891,247	868,760	905,769	945,447	994,055
Accumulated other comprehensive income (loss)	14,966	12,170	(2,961)	20,223	7,871	614	26,483	(14,043)	10,746	63,850	61,647	58,202
Total stockholders' equity	1,417,936	1,445,655	1,463,349	1,519,042	1,525,011	1,553,910	1,621,186	1,619,215	1,606,704	1,703,537	1,745,837	1,746,643
Total liabilities and stockholders' equity	\$ 2,873,550	\$ 2,861,344	\$ 2,839,349	\$ 2,942,653	\$ 3,116,009	\$ 3,126,412	\$ 3,167,649	\$ 3,077,971	\$ 3,297,703	\$ 3,370,935	\$ 3,397,310	\$ 3,410,577
TOTAL DEBT:												
Current portion of long-term debt	\$ 10,000	\$ 5,000	\$ -	\$ -	\$ -	\$ -	\$ 5,000	\$ 10,000	\$ 11	\$ -	\$ -	\$ -
Long-term debt	992,469	980,398	941,383	959,925	1,140,724	1,118,529	1,074,339	980,153	1,235,204	1,202,495	1,193,826	1,185,179
Total debt	\$ 1,002,469	\$ 985,398	\$ 941,383	\$ 959,925	\$ 1,140,724	\$ 1,118,529	\$ 1,079,339	\$ 990,153	\$ 1,235,215	\$ 1,202,495	\$ 1,193,826	\$ 1,185,179
NET TOTAL DEBT (Non-GAAP)⁽¹⁾ & LEVERAGE RATIO (Non-GAAP)⁽²⁾												
Revolving credit facility	\$ 119,040	\$ 108,640	\$ 81,247	\$ 99,000	\$ 279,000	\$ 256,000	\$ 216,000	\$ 126,000	\$ -	\$ 10,000	\$ -	\$ -
Term A loan ("TLA Facility")	400,000	392,500	375,000	375,000	375,000	375,000	375,000	375,000	145,000	101,000	101,000	91,000
Convertible notes due 2028	500,000	500,000	500,000	500,000	500,000	500,000	499,998	499,994	116,312	116,301	116,297	116,284
Convertible notes due 2030	-	-	-	-	-	-	-	-	1,000,000	1,000,000	1,000,000	1,000,000
Total principal amount of debt outstanding	1,019,040	1,001,140	956,247	974,000	1,154,000	1,131,000	1,090,998	1,000,994	1,261,312	1,227,301	1,217,297	1,207,284
Unamortized discount and debt issuance costs	(16,571)	(15,742)	(14,864)	(14,075)	(13,276)	(12,471)	(11,659)	(10,841)	(26,097)	(24,806)	(23,471)	(22,105)
Total debt	\$ 1,002,469	\$ 985,398	\$ 941,383	\$ 959,925	\$ 1,140,724	\$ 1,118,529	\$ 1,079,339	\$ 990,153	\$ 1,235,215	\$ 1,202,495	\$ 1,193,826	\$ 1,185,179
Total principal amount of debt outstanding	\$ 1,019,040	\$ 1,001,140	\$ 956,247	\$ 974,000	\$ 1,154,000	\$ 1,131,000	\$ 1,090,998	\$ 1,000,994	\$ 1,261,312	\$ 1,227,301	\$ 1,217,297	\$ 1,207,284
LESS: Cash and cash equivalents	(40,604)	(38,615)	(32,142)	(23,674)	(42,156)	(34,137)	(35,574)	(46,543)	(31,711)	(23,135)	(58,944)	(17,161)
Net Total Debt (Non-GAAP)	\$ 978,436	\$ 962,525	\$ 924,105	\$ 950,326	\$ 1,111,844	\$ 1,096,863	\$ 1,055,424	\$ 954,451	\$ 1,229,601	\$ 1,204,166	\$ 1,158,353	\$ 1,190,123
Trailing 4 quarters Adjusted EBITDA				\$ 309,336	\$ 324,229	\$ 339,049	\$ 351,416	\$ 360,663	\$ 371,943	\$ 381,052	\$ 391,424	\$ 402,348
Leverage ratio (Non-GAAP)				3.1	3.4	3.2	3.0	2.6	3.3	3.2	3.0	3.0

Balance Sheets Trend

(\$ in thousands, except per share data; unaudited)



	2023				2024				2025			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
OTHER DEBT-RELATED RATIOS AND RATES												
Total net leverage ratio (calculated in accordance with the applicable credit agreement governing the Senior Secured Credit Facilities):												
Maximum allowed	5.50	5.50	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Actual	3.1	2.9	2.7	2.6	2.8	2.7	2.6	2.3	2.8	2.7	2.6	2.7
Interest coverage ratio of adjusted EBITDA (calculated in accordance with the applicable credit agreement governing Senior Secured Credit Facilities):												
Minimum required	2.50	2.50	2.50	2.50	2.50	2.50	2.50	2.50	2.50	2.50	2.50	2.50
Actual	7.7	7.9	7.7	9.2	8.5	8.0	7.8	8.1	8.6	10.4	11.2	13.6
Applicable interest rate spreads (bp), end of period (transitioned index from LIBOR to SOFR during 1Q 2023):												
Revolving credit facility (LIBOR/SOFR +) US loans	175	150	150	150	150	150	150	150	150	125	125	125
Revolving credit facility (EURIBOR +) Euro loans	175	150	150	150	150	150	150	150	150	125	125	125
Swingline facility (PRIME +)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	25	N/A	N/A
TLA Facility (LIBOR/SOFR +)	175	150	150	150	150	150	150	150	150	125	125	125
Weighted average contractual interest rates, end of period:												
Revolving credit / Swingline facility	4.76%	4.92%	6.47%	7.08%	6.93%	6.94%	6.46%	5.96%	5.93%	7.75%	N/A	N/A
TLA Facility (excluding rate swap impact, if applicable)	6.66%	6.70%	6.92%	6.96%	6.93%	6.94%	6.46%	5.96%	5.93%	5.67%	5.51%	5.07%
Convertible Senior Notes due 2028 ("2028 Convertible Notes"):												
Fixed interest rate	2.125%	2.125%	2.125%	2.125%	2.125%	2.125%	2.125%	2.125%	2.125%	2.125%	2.125%	2.125%
Effective interest rate	2.76%	2.76%	2.76%	2.76%	2.76%	2.76%	2.76%	2.76%	2.76%	2.76%	2.76%	2.76%
Convertible Senior Notes due 2030 ("2030 Convertible Notes"):												
Fixed interest rate	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	1.875%	1.875%	1.875%	1.875%
Effective interest rate	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	2.38%	2.38%	2.38%	2.38%
Weighted average interest rates, periodic:												
Effective interest rate on borrowings (GAAP)	6.99%	4.52%	4.91%	5.14%	5.20%	5.31%	5.39%	5.09%	4.73%	3.00%	2.97%	2.99%
Less: Impact of loss on extinguishment of debt	1.79%	0.02%	0.04%	0.00%	0.00%	0.00%	0.00%	0.00%	0.25%	0.04%	0.00%	0.01%
Adjusted effective interest rate on borrowings (Non-GAAP)	5.20%	4.50%	4.87%	5.14%	5.20%	5.31%	5.39%	5.09%	4.48%	2.96%	2.97%	2.98%

Statements of Operations Trend

(\$ in thousands, except per share data; unaudited)



	2023				2024				2025			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Statements of Operations (GAAP)												
Sales	\$ 364,671	\$ 389,678	\$ 396,803	\$ 404,504	\$ 407,796	\$ 427,886	\$ 431,417	\$ 449,497	\$ 437,392	\$ 476,494	\$ 467,691	\$ 472,060
Cost of sales	273,156	285,858	291,813	294,940	299,523	310,509	314,849	332,701	317,074	347,342	341,531	347,304
Gross profit	91,515	103,820	104,990	109,564	108,273	117,377	116,568	116,796	120,318	129,152	126,160	124,756
Operating expenses:												
Selling, general and administrative	41,498	44,933	41,444	45,296	46,435	46,479	44,820	47,468	51,160	52,923	50,451	57,214
Research, development and engineering	18,536	16,313	14,068	13,050	15,274	15,614	11,923	10,614	14,201	14,240	10,949	10,109
Restructuring and other charges	1,522	1,518	702	7,686	7,863	790	1,814	1,682	5,405	2,651	8,321	1,498
Total operating expenses	61,556	62,764	56,214	66,032	69,572	62,883	58,557	59,764	70,766	69,814	69,721	68,821
Operating income	29,959	41,056	48,776	43,532	38,701	54,494	58,011	57,032	49,552	59,338	56,439	55,935
Interest expense	16,724	11,004	11,493	12,054	13,991	14,572	14,577	13,234	14,805	9,754	9,367	9,280
(Gain) loss on equity investments	155	(134)	3,451	2,219	(1,136)	7	(906)	2,815	(181)	8	(50)	(327)
Other (income) loss, net	760	359	580	(724)	1,007	(127)	916	1,725	47,927	3,980	1,130	175
Income (loss) from continuing operations before taxes	12,320	29,827	33,252	29,983	24,839	40,042	43,424	39,258	(12,999)	45,596	45,992	46,807
Provision for income taxes	2,172	5,819	5,078	3,170	4,248	8,835	7,142	6,285	9,466	8,587	6,314	(1,801)
Income (loss) from continuing operations	\$ 10,148	\$ 24,008	\$ 28,174	\$ 26,813	\$ 20,591	\$ 31,207	\$ 36,282	\$ 32,973	\$ (22,465)	\$ 37,009	\$ 39,678	\$ 48,608
Discontinued operations:												
Income (loss) from discontinued operations before taxes	3,677	65	(1,175)	(655)	(104)	(14)	(183)	(515)	(22)	-	-	-
Provision (benefit) for income taxes	760	102	(258)	(199)	(21)	(53)	660	(245)	-	-	-	-
Income (loss) from discontinued operations	\$ 2,917	\$ (37)	\$ (917)	\$ (456)	\$ (83)	\$ 39	\$ (843)	\$ (270)	\$ (22)	\$ -	\$ -	\$ -
Net income (loss)	\$ 13,065	\$ 23,971	\$ 27,257	\$ 26,357	\$ 20,508	\$ 31,246	\$ 35,439	\$ 32,703	\$ (22,487)	\$ 37,009	\$ 39,678	\$ 48,608
Basic earnings (loss) per share:												
Income (loss) from continuing operations	\$ 0.31	\$ 0.72	\$ 0.84	\$ 0.80	\$ 0.62	\$ 0.93	\$ 1.08	\$ 0.98	\$ (0.66)	\$ 1.06	\$ 1.13	\$ 1.39
Income (loss) from discontinued operations	0.09	-	(0.03)	(0.01)	-	-	(0.03)	(0.01)	-	-	-	-
Basic earnings (loss) per share	0.39	0.72	0.82	0.79	0.61	0.93	1.05	0.97	(0.66)	1.06	1.13	1.39
Diluted earnings (loss) per share (Diluted EPS):												
Income (loss) from continuing operations	\$ 0.30	\$ 0.71	\$ 0.83	\$ 0.79	\$ 0.59	\$ 0.88	\$ 1.01	\$ 0.91	\$ (0.66)	\$ 1.04	\$ 1.11	\$ 1.38
Income (loss) from discontinued operations	0.09	-	(0.03)	(0.01)	-	-	(0.02)	(0.01)	-	-	-	-
Diluted earnings (loss) per share	0.39	0.71	0.81	0.78	0.59	0.88	0.99	0.90	(0.66)	1.04	1.11	1.38
Weighted average shares outstanding:												
Basic	33,258	33,312	33,346	33,364	33,478	33,600	33,656	33,665	33,916	35,035	35,081	34,865
Diluted	33,575	33,686	33,774	33,987	34,993	35,529	35,791	36,243	33,916	35,713	35,608	35,144

Statements of Operations Trend

(\$ in thousands, except per share data; unaudited)



	2023				2024				2025			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Adjusted Operating Income (Non-GAAP)⁽³⁾												
Operating income from continuing operations (GAAP)	\$ 29,959	\$ 41,056	\$ 48,776	\$ 43,532	\$ 38,701	\$ 54,494	\$ 58,011	\$ 57,032	\$ 49,552	\$ 59,338	\$ 56,439	\$ 55,935
Non-GAAP adjustments for Adjusted Operating Income:												
Amortization of intangible assets	12,840	13,023	13,021	13,307	13,351	13,609	13,626	14,028	14,851	16,120	16,249	17,128
Certain legal expenses	-	-	-	-	-	354	481	304	102	9	181	354
Restructuring and restructuring-related charges	1,798	2,894	470	4,787	1,887	1,935	1,916	1,517	1,102	2,575	2,749	3,767
Acquisition and integration costs	382	556	777	1,729	6,335	1,056	1,017	533	4,742	2,007	1,372	44
Other general expenses (gains)	83	26	28	1,973	118	(1,173)	83	167	(1)	7	6,247	1,173
ERP implementation	-	-	-	-	-	-	-	-	-	-	-	1,651
Medical device regulations	502	534	205	364	275	278	209	186	250	262	183	338
Other adjustments	-	909	1,319	1,187	472	272	304	2,208	325	948	2,476	2,895
Inventory step-up amortization	-	-	-	590	1,056	-	-	-	-	-	-	-
Total non-GAAP adjustments	15,605	17,942	15,820	23,937	23,494	16,331	17,636	18,943	21,371	21,928	29,457	27,350
Adjusted operating income (Non-GAAP)	\$ 45,564	\$ 58,998	\$ 64,596	\$ 67,469	\$ 62,195	\$ 70,825	\$ 75,647	\$ 75,975	\$ 70,923	\$ 81,266	\$ 85,896	\$ 83,285
Adjusted Net Income (Non-GAAP)⁽⁴⁾												
Income from continuing operations (GAAP)	\$ 10,148	\$ 24,008	\$ 28,174	\$ 26,813	\$ 20,591	\$ 31,207	\$ 36,282	\$ 32,973	\$ (22,465)	\$ 37,009	\$ 39,678	\$ 48,608
Non-GAAP adjustments for Adjusted Income:												
Amortization of intangible assets	12,840	13,023	13,021	13,307	13,351	13,609	13,626	14,028	14,851	16,120	16,249	17,128
Certain legal expenses	-	-	-	-	-	354	481	304	102	9	181	354
Restructuring and restructuring-related charges	1,798	2,894	470	4,787	1,887	1,935	1,916	1,517	1,102	2,575	2,749	3,767
Acquisition and integration costs	382	556	777	1,729	6,335	1,056	1,017	533	4,742	2,007	1,372	44
Other general expenses (gains)	83	26	28	1,973	118	(1,173)	83	167	(1)	7	6,247	1,173
ERP implementation	-	-	-	-	-	-	-	-	-	-	-	1,651
(Gain) loss on equity investments, net	155	(134)	3,451	2,219	(1,136)	7	(906)	2,815	(181)	8	(50)	(327)
Loss on extinguishment of debt	4,393	38	87	-	-	-	-	-	737	130	-	26
Debt conversion inducement expense	-	-	-	-	-	-	-	-	46,681	-	-	-
Medical device regulations	502	534	205	364	275	278	209	186	250	262	183	338
Other adjustments	-	909	1,319	1,187	472	272	304	2,208	325	948	2,476	2,895
Inventory step-up amortization	-	-	-	590	1,056	-	-	-	-	-	-	-
Tax and other non-recurring adjustments, after tax	66	63	120	116	106	274	165	111	4,161	107	107	(8,455)
Total non-GAAP adjustments before tax	20,219	17,909	19,478	26,272	22,464	16,612	16,895	21,869	72,769	22,173	29,514	18,594
Tax provision related to non-GAAP adjustments	4,296	3,750	4,014	5,331	4,387	3,136	3,345	4,337	4,366	4,364	6,066	5,424
Total non-GAAP adjustments after tax	15,923	14,159	15,464	20,941	18,077	13,476	13,550	17,532	68,403	17,809	23,448	13,170
Adjusted net income (Non-GAAP)	\$ 26,071	\$ 38,167	\$ 43,638	\$ 47,754	\$ 38,668	\$ 44,683	\$ 49,832	\$ 50,505	\$ 45,938	\$ 54,818	\$ 63,126	\$ 61,778

Statements of Operations Trend

(\$ in thousands, except per share data; unaudited)



	2023				2024				2025			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Adjusted EPS (Non-GAAP)⁽⁵⁾ & Adjusted Weighted Average Shares (Non-GAAP)⁽⁶⁾												
Diluted EPS from continuing operations (GAAP)	\$ 0.30	\$ 0.71	\$ 0.83	\$ 0.79	\$ 0.59	\$ 0.88	\$ 1.01	\$ 0.91	\$ (0.66)	\$ 1.04	\$ 1.11	\$ 1.38
Non-GAAP adjustments (per share) for Adjusted EPS:												
Amortization of intangible assets	0.30	0.31	0.30	0.31	0.32	0.32	0.32	0.32	0.34	0.37	0.37	0.39
Certain legal expenses	-	-	-	-	-	0.01	0.01	0.01	-	-	-	0.01
Restructuring and restructuring-related charges	0.04	0.07	0.01	0.12	0.05	0.04	0.04	0.03	0.03	0.06	0.06	0.10
Acquisition and integration costs	0.01	0.01	0.02	0.04	0.15	0.02	0.02	0.01	0.11	0.04	0.03	0.01
Other general expenses (gains)	-	-	-	0.04	-	(0.02)	-	-	-	-	0.13	-
ERP implementation	-	-	-	-	-	-	-	-	-	-	-	0.04
(Gain) loss on equity investments, net	-	-	0.08	0.05	(0.03)	-	(0.02)	0.06	-	-	-	(0.01)
Loss on extinguishment of debt	0.10	-	-	-	-	-	-	-	0.02	-	-	-
Debt conversion inducement expense	-	-	-	-	-	-	-	-	1.33	0.01	-	-
Medical device regulations	0.01	0.01	-	0.01	0.01	0.01	-	-	0.01	0.02	-	0.01
Other adjustments	-	0.02	0.03	0.03	0.01	0.01	0.01	0.05	0.01	-	0.06	0.07
Inventory step-up amortization	-	-	-	0.01	0.02	-	-	-	-	-	-	-
Tax adjustments	-	-	-	-	-	-	-	-	0.12	-	-	(0.24)
Impact of capped call option contracts	-	-	-	-	0.02	0.03	0.03	0.02	0.02	-	0.01	-
Adjusted EPS (Non-GAAP)	\$ 0.78	\$ 1.13	\$ 1.29	\$ 1.41	\$ 1.14	\$ 1.30	\$ 1.43	\$ 1.43	\$ 1.31	\$ 1.55	\$ 1.79	\$ 1.76
Weighted average shares for diluted EPS (GAAP)	33,575	33,686	33,774	33,987	34,993	35,529	35,791	36,243	33,916	35,713	35,608	35,144
Add: Dilutive common stock equivalents*	-	-	-	-	-	-	-	-	2,036	-	-	-
Less: Convertible Notes capped call options impact	-	-	-	-	(1,028)	(1,050)	(1,003)	(920)	(803)	(240)	(261)	-
Adjusted weighted average shares (non-GAAP)	33,575	33,686	33,774	33,987	33,965	34,479	34,788	35,323	35,149	35,473	35,347	35,144

* Excluded from GAAP weighted average shares for diluted EPS for the period due to the loss from continuing operations.

Statements of Operations Trend

(\$ in thousands, except per share data; unaudited)



	2023				2024				2025			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
EBITDA (Non-GAAP)⁽⁷⁾ & Adjusted EBITDA (Non-GAAP)⁽⁸⁾												
Income from continuing operations (GAAP)	\$ 10,148	\$ 24,008	\$ 28,174	\$ 26,813	\$ 20,591	\$ 31,207	\$ 36,282	\$ 32,973	\$ (22,465)	\$ 37,009	\$ 39,678	\$ 48,608
Interest expense	16,724	11,004	11,493	12,054	13,991	14,572	14,577	13,234	14,805	9,754	9,367	9,280
Provision (benefit) for income taxes	2,172	5,819	5,078	3,170	4,248	8,835	7,142	6,285	9,466	8,587	6,314	(1,801)
Depreciation ^(a)	10,687	10,814	10,836	11,097	11,814	12,585	14,025	14,095	13,986	15,040	15,562	17,014
Amortization of intangible assets and financing leases ^(a)	13,165	13,354	13,363	13,676	13,852	14,184	14,320	14,832	15,846	17,246	17,478	18,495
EBITDA (Non-GAAP)	52,896	64,999	68,944	66,810	64,496	81,383	86,346	81,419	31,638	87,636	88,399	91,596
Stock-based compensation ^(a)	5,921	5,467	5,487	6,160	6,726	5,730	6,076	5,917	6,851	5,499	4,341	4,499
Certain legal expenses	-	-	-	-	-	354	481	304	102	9	181	354
Restructuring and restructuring-related charges	1,798	2,894	470	4,787	1,887	1,935	1,916	1,517	1,102	2,575	2,749	3,767
Acquisition and integration costs	382	556	777	1,729	6,335	1,056	1,017	533	4,742	2,007	1,372	44
Other general expenses (gains)	83	26	28	1,973	118	(1,173)	83	167	(1)	7	6,247	1,173
ERP implementation	-	-	-	-	-	-	-	-	-	-	-	1,651
(Gain) loss on equity investments, net	155	(134)	3,451	2,219	(1,136)	7	(906)	2,815	(181)	8	(50)	(327)
Debt conversion inducement expense	-	-	-	-	-	-	-	-	46,681	-	-	-
Medical device regulations	502	534	205	364	275	278	209	186	250	262	183	338
Other adjustments	-	909	1,319	1,187	472	272	304	2,208	325	948	2,476	2,895
Inventory step-up amortization	-	-	-	590	1,056	-	-	-	-	-	-	-
Adjusted EBITDA (Non-GAAP)	\$ 61,737	\$ 75,251	\$ 80,681	\$ 85,819	\$ 80,229	\$ 89,842	\$ 95,526	\$ 95,066	\$ 91,509	\$ 98,951	\$ 105,898	\$ 105,990

^(a) When applicable, excludes amounts included in Restructuring and restructuring-related charges.

Statements of Operations Trend

(\$ in thousands, except per share data; unaudited)



	2023				2024				2025			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Adjusted Interest Expense (Non-GAAP)⁽⁹⁾												
Interest expense on borrowings (GAAP)	\$ 16,594	\$ 10,898	\$ 11,473	\$ 11,909	\$ 13,846	\$ 14,419	\$ 14,369	\$ 12,943	\$ 14,367	\$ 9,377	\$ 9,002	\$ 8,872
Less: Loss on extinguishment of debt	(4,393)	(38)	(87)	-	-	-	-	-	(737)	(130)	-	(26)
Adjusted Interest Expense on Borrowings (Non-GAAP)	\$ 12,201	\$ 10,860	\$ 11,386	\$ 11,909	\$ 13,846	\$ 14,419	\$ 14,369	\$ 12,943	\$ 13,630	\$ 9,247	\$ 9,002	\$ 8,846
Add: Other interest expense	130	107	18	146	145	153	208	291	438	377	365	408
Adjusted Total Interest Expense (Non-GAAP)	\$ 12,331	\$ 10,967	\$ 11,404	\$ 12,055	\$ 13,991	\$ 14,572	\$ 14,577	\$ 13,234	\$ 14,068	\$ 9,624	\$ 9,367	\$ 9,254

Adjusted Effective Tax Rate (Non-GAAP)⁽¹⁰⁾												
Effective tax rate from continuing operations (GAAP)	17.6%	19.5%	15.3%	10.6%	17.1%	22.1%	16.4%	16.0%	-72.8%	18.8%	13.7%	-3.8%
Impact on income tax provision related to Non-GAAP adjustments	2.1%	0.4%	1.8%	4.3%	1.0%	-1.4%	0.8%	1.2%	90.2%	0.2%	2.6%	20.2%
Adjusted effective tax rate (Non-GAAP)	19.7%	19.9%	17.1%	14.9%	18.1%	20.7%	17.2%	17.2%	17.4%	19.0%	16.3%	16.4%

YEAR-TO-DATE												
Effective tax rate from continuing operations (GAAP)	17.6%	19.0%	17.3%	15.4%	17.1%	20.2%	18.7%	18.0%	-72.8%	55.4%	31.0%	18.0%
Impact on income tax provision related to Non-GAAP adjustments	2.1%	0.8%	1.4%	2.2%	1.0%	-0.7%	0.0%	0.3%	90.2%	-37.1%	-13.5%	-0.8%
Adjusted effective tax rate (Non-GAAP)	19.7%	19.8%	18.7%	17.6%	18.1%	19.5%	18.7%	18.3%	17.4%	18.3%	17.5%	17.2%

Statements of Cash Flows Trend

(\$ in thousands; unaudited)



	2023				2024				2025			
	YTD 1Q	YTD 2Q	YTD 3Q	YTD 4Q	YTD 1Q	YTD 2Q	YTD 3Q	YTD 4Q	YTD 1Q	YTD 2Q	YTD 3Q	YTD 4Q
Statements of Cash Flows (GAAP) (includes cash flows from both continuing and discontinued operations)												
Cash flows from operating activities:												
Net income	\$ 13,065	\$ 37,073	\$ 64,293	\$ 90,650	\$ 20,508	\$ 51,754	\$ 87,193	\$ 119,896	\$ (22,487)	\$ 14,522	\$ 54,200	\$ 102,808
Adjustments to reconcile net income to net cash provided by operating activities:												
Depreciation and amortization	23,852	48,020	73,116	98,841	26,185	53,410	82,104	111,031	29,832	62,118	95,158	130,667
Debt related charges included in interest expense	5,149	6,118	7,126	8,054	931	1,869	2,962	4,057	1,882	3,627	5,239	6,882
Debt conversion inducement expense	-	-	-	-	-	-	-	-	46,681	46,681	46,681	46,681
Inventory step-up amortization	-	-	-	590	1,056	1,056	1,056	1,056	-	-	-	-
Stock-based compensation	6,102	11,603	17,099	23,283	6,848	12,614	18,729	24,767	6,880	12,536	17,467	23,224
Non-cash lease expense	2,741	5,473	8,124	11,248	2,295	4,622	6,928	9,125	2,455	5,000	7,583	10,160
Non-cash (gain) loss on equity investments	155	21	3,472	5,691	(1,136)	(1,129)	(2,035)	780	(181)	(173)	(223)	(550)
Contingent consideration fair value adjustment	(265)	(265)	(526)	(736)	-	-	-	(3,550)	-	(309)	(660)	(2,266)
Other non-cash (gains) losses	(1,417)	(1,437)	(734)	4,379	805	1,408	4,433	6,954	2,574	3,143	804	1,693
Deferred income taxes	(5)	(4)	(5)	(9,490)	-	-	-	(14,110)	4,055	3,942	4,082	(2,687)
Gain on sale of discontinued operations	-	-	-	-	-	-	-	(177)	(46)	(46)	(46)	(46)
Changes in operating assets and liabilities, net of acquisitions:												
Accounts receivable	(24,206)	(9,742)	(58)	(7,437)	7,667	3,465	(4,888)	(6,532)	(18,232)	(41,014)	(46,793)	(82,382)
Inventories	(17,016)	(21,646)	(25,785)	(30,178)	(17,271)	(27,235)	(31,515)	(18,079)	(7,695)	(14,509)	(12,241)	(2,576)
Contract assets	(8,819)	(7,983)	(14,863)	(13,646)	(5,255)	(11,666)	(13,159)	(18,447)	1,219	1,800	(2,106)	(7,277)
Prepaid expenses and other assets	1,657	1,308	(1,473)	(930)	(4,208)	(744)	(495)	(229)	(1,169)	71	117	(2,495)
Accounts payable	12,877	797	(869)	(520)	2,669	7,069	4,295	(16,620)	10,207	11,561	3,187	(566)
Accrued expenses and other liabilities	(7,773)	1,781	7,401	7,908	(19,026)	(16,155)	(5,355)	4,472	(23,495)	(23,312)	(22,359)	(20,269)
Income taxes	(183)	(9,296)	(11,692)	(7,494)	1,171	(9,864)	(8,279)	811	(1,204)	(10,500)	(9,357)	(4,853)
Net cash provided by operating activities	5,914	61,821	124,626	180,213	23,239	70,474	141,974	205,205	31,276	75,138	140,733	196,148
Cash flows from investing activities:												
Acquisition of PP&E and intangible assets	(24,694)	(57,416)	(82,885)	(119,938)	(29,072)	(60,252)	(86,517)	(105,607)	(25,218)	(44,219)	(63,555)	(91,032)
Proceeds from sale of PP&E	-	50	100	173	-	-	30	39	5	19	37	45
Proceeds from return of capital from equity investments	-	-	-	-	-	-	-	-	-	78	78	78
Acquisitions, net of cash acquired	-	-	-	(43,602)	(139,126)	(138,544)	(138,544)	(138,544)	(171,954)	(170,872)	(170,872)	(178,872)
Proceeds from sale of discontinued operations	-	-	-	-	-	-	-	48,698	-	-	(950)	(950)
Net cash used in investing activities	(24,694)	(57,366)	(82,785)	(163,367)	(168,198)	(198,796)	(225,031)	(195,414)	(197,167)	(214,994)	(235,262)	(270,731)

Statements of Cash Flows Trend

(\$ in thousands; unaudited)



	2023				2024				2025			
	YTD 1Q	YTD 2Q	YTD 3Q	YTD 4Q	YTD 1Q	YTD 2Q	YTD 3Q	YTD 4Q	YTD 1Q	YTD 2Q	YTD 3Q	YTD 4Q
Cash flows from financing activities:												
Principal payments of term loans and long-term debt	(390,938)	(398,438)	(415,938)	(415,938)	-	-	(2)	(6)	(613,683)	(657,693)	(657,697)	(667,710)
Proceeds from issuance of long-term debt, net of discount	486,250	486,250	486,250	486,250	-	-	-	-	977,500	977,500	977,500	977,500
Proceeds from revolving credit facility	208,689	229,604	294,603	383,103	192,000	208,500	234,500	274,500	216,000	257,000	301,000	307,000
Payments of revolving credit facility	(232,500)	(263,443)	(353,993)	(424,801)	(12,000)	(51,500)	(117,500)	(247,500)	(342,000)	(373,000)	(427,000)	(433,000)
Purchase of capped calls	(35,000)	(35,000)	(35,000)	(35,000)	-	-	-	-	(71,000)	(71,000)	(71,000)	(71,000)
Payment of debt issuance costs	(1,055)	(2,181)	(2,181)	(2,181)	-	-	(2,071)	(2,075)	-	(1,266)	(1,386)	(1,386)
Repurchases of common stock	-	-	-	-	-	-	-	-	-	-	-	(50,014)
Proceeds from the exercise of stock options	555	1,948	2,303	2,303	313	742	742	742	-	3,644	3,644	3,644
Tax withholdings related to net share settlement of RSUs	(2,610)	(2,930)	(3,067)	(3,098)	(9,348)	(10,625)	(10,773)	(10,938)	(14,132)	(16,707)	(16,812)	(16,918)
Payment of contingent consideration	-	(7,660)	(7,660)	(7,660)	-	-	-	-	-	-	-	-
Principal payments on finance leases	(275)	(557)	(854)	(992)	(8,386)	(8,956)	(9,772)	(10,723)	(1,177)	(2,596)	(4,165)	(5,924)
Other financing activities	-	-	-	-	715	607	501	9,321	70	107	1,194	1,366
Net cash provided by (used in) financing activities	33,116	7,593	(35,537)	(18,014)	163,294	138,768	95,625	13,321	151,578	115,989	105,278	43,558
Effect of foreign currency exchange rates on cash and cash equivalents	1,722	1,783	1,566	570	147	17	(668)	(243)	(519)	459	1,652	1,643
Net increase (decrease) in cash and cash equivalents	16,058	13,831	7,870	(598)	18,482	10,463	11,900	22,869	(14,832)	(23,408)	12,401	(29,382)
Cash and cash equivalents, beginning of period	24,272	24,272	24,272	24,272	23,674	23,674	23,674	23,674	46,543	46,543	46,543	46,543
Cash and cash equivalents, end of period	\$ 40,330	\$ 38,103	\$ 32,142	\$ 23,674	\$ 42,156	\$ 34,137	\$ 35,574	\$ 46,543	\$ 31,711	\$ 23,135	\$ 58,944	\$ 17,161

Free Cash Flow (Non-GAAP)⁽¹¹⁾

YEAR-TO-DATE

Net cash provided by operating activities	5,914	61,821	124,626	180,213	23,239	70,474	141,974	205,205	31,276	75,138	140,733	196,148
Less: Capital expenditures, net	(24,694)	(57,366)	(82,785)	(119,765)	(29,072)	(60,252)	(86,487)	(105,568)	(25,213)	(44,200)	(63,518)	(90,987)
Free cash flow (YTD)	(18,780)	4,455	41,841	60,448	(5,833)	10,222	55,487	99,637	6,063	30,938	77,215	105,161

QUARTER-TO-DATE

	(18,780)	23,235	37,386	18,607	(5,833)	16,055	45,265	44,150	6,063	24,875	46,277	27,946
--	----------	--------	--------	--------	---------	--------	--------	--------	-------	--------	--------	--------

Sales Trend

(\$ in thousands; unaudited)



	2023				2024				2025			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Sales (GAAP)												
Product Line Sales												
Cardio & Vascular	\$ 191,204	\$ 208,493	\$ 214,004	\$ 222,642	\$ 221,851	\$ 231,418	\$ 241,009	\$ 255,298	\$ 258,871	\$ 286,855	\$ 277,149	\$ 284,209
Cardiac Rhythm Management & Neuromodulation	145,544	153,978	160,121	153,248	156,931	168,061	165,094	170,524	160,345	171,998	169,156	167,304
Other Markets	27,923	27,207	22,678	28,614	29,014	28,407	25,314	23,675	18,176	17,641	21,386	20,547
Total Sales (GAAP)	\$ 364,671	\$ 389,678	\$ 396,803	\$ 404,504	\$ 407,796	\$ 427,886	\$ 431,417	\$ 449,497	\$ 437,392	\$ 476,494	\$ 467,691	\$ 472,060

QUARTER OVER PRIOR YEAR QUARTER CHANGE (\$)

Product Line Sales												
Cardio & Vascular					\$ 30,647	\$ 22,925	\$ 27,005	\$ 32,656	\$ 37,020	\$ 55,437	\$ 36,140	\$ 28,911
Cardiac Rhythm Management & Neuromodulation					11,387	14,083	4,973	17,276	3,414	3,937	4,062	(3,220)
Other Markets					1,091	1,200	2,636	(4,939)	(10,838)	(10,766)	(3,928)	(3,128)
Total Sales (GAAP)					\$ 43,125	\$ 38,208	\$ 34,614	\$ 44,993	\$ 29,596	\$ 48,608	\$ 36,274	\$ 22,563

QUARTER OVER PRIOR YEAR QUARTER CHANGE (%)

Product Line Sales												
Cardio & Vascular					16.0%	11.0%	12.6%	14.7%	16.7%	24.0%	15.0%	11.3%
Cardiac Rhythm Management & Neuromodulation					7.8%	9.1%	3.1%	11.3%	2.2%	2.3%	2.5%	-1.9%
Other Markets					3.9%	4.4%	11.6%	-17.3%	-37.4%	-37.9%	-15.5%	-13.2%
Total Sales (GAAP)					11.8%	9.8%	8.7%	11.1%	7.3%	11.4%	8.4%	5.0%

Sales Trend

(\$ in thousands; unaudited)



	2023				2024				2025			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Organic Sales Change (Non-GAAP)⁽¹²⁾												
Cardio & Vascular												
Quarter over Prior Year Quarter Change in Sales (GAAP)					16.0%	11.0%	12.6%	14.7%	16.7%	24.0%	15.0%	11.3%
Impact of foreign currency					0.1%	-0.1%	0.1%	0.0%	-0.2%	0.3%	0.3%	0.4%
Impact of strategic exits and acquisitions					6.6%	6.8%	6.3%	3.3%	6.0%	6.1%	6.2%	6.5%
Quarter over Prior Year Quarter Change in Organic Sales (Non-GAAP)					9.3%	4.3%	6.2%	11.4%	10.9%	17.6%	8.5%	4.4%
Cardiac Rhythm Management & Neuromodulation												
Quarter over Prior Year Quarter Change in Sales (GAAP)					7.8%	9.1%	3.1%	11.3%	2.2%	2.3%	2.5%	-1.9%
Impact of foreign currency					0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Impact of strategic exits and acquisitions					0.8%	0.9%	0.9%	1.1%	0.0%	0.0%	0.0%	0.0%
Quarter over Prior Year Quarter Change in Organic Sales (Non-GAAP)					7.0%	8.2%	2.2%	10.2%	2.2%	2.3%	2.5%	-1.9%
Other Markets												
Quarter over Prior Year Quarter Change in Sales (GAAP)					3.9%	4.4%	11.6%	-17.3%	-37.4%	-37.9%	-15.5%	-13.2%
Impact of foreign currency					0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%
Impact of strategic exits and acquisitions					-12.0%	-0.4%	12.6%	-17.7%	-14.5%	-36.1%	-43.1%	-19.1%
Quarter over Prior Year Quarter Change in Organic Sales (Non-GAAP)					15.9%	4.8%	-1.0%	0.4%	-22.9%	-1.8%	27.5%	5.9%
TOTAL SALES												
Quarter over Prior Year Quarter Change in Sales (GAAP)					11.8%	9.8%	8.7%	11.1%	7.3%	11.4%	8.4%	5.0%
Impact of foreign currency					0.0%	0.0%	0.1%	0.0%	-0.1%	0.2%	0.2%	0.2%
Impact of strategic exits and acquisitions					3.2%	3.9%	4.3%	0.5%	1.1%	0.4%	1.6%	2.8%
Quarter over Prior Year Quarter Change in Organic Sales (Non-GAAP)					8.6%	5.9%	4.3%	10.6%	6.3%	10.8%	6.6%	2.0%

BASIS OF PRESENTATION

Unless otherwise noted, all information presented in the schedules refers to continuing operations.

PERIOD END DATES

Quarter	2023				2024				2025			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Quarterly period end	03/31/23	06/30/23	09/29/23	12/31/23	03/29/24	06/28/24	09/27/24	12/31/24	03/28/25	06/27/25	09/26/25	12/31/25
Days in period	90	91	91	93	89	91	91	95	87	91	91	96

NON-GAAP FINANCIAL INFORMATION

The Company uses non-GAAP financial measures, including the measures provided in these schedules, to describe its operating results. Our management team believes that the presentation of these measures provides useful information to investors and that these measures may assist investors in evaluating the Company's operations period over period. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

- (1) Net Total Debt is calculated as total principal amount of debt outstanding less cash and cash equivalents.
- (2) Leverage ratio, sometimes referred to as Leverage or Debt Leverage, is calculated by dividing Net Total Debt by Adjusted EBITDA for the trailing 4 quarters.
- (3) Adjusted Operating Income is calculated by adding back amortization of intangible assets, certain legal expenses, restructuring and restructuring-related charges, acquisition and integration costs, other general expenses, ERP implementation, European Union medical device regulation incremental charges, other adjustments, and inventory step-up amortization, to operating income (loss) from continuing operations.
- (4) Adjusted Net Income is calculated by adding back amortization of intangible assets, certain legal expenses, restructuring and restructuring-related charges, acquisition and integration costs, other general expenses, ERP implementation, (gain) loss on equity investments, extinguishment of debt charges, debt conversion inducement expense, European Union medical device regulation incremental charges, other adjustments, inventory step-up amortization, the income tax provision (benefit) related to these adjustments, and certain tax items that are outside the normal provision for the period, to income from continuing operations.
- (5) Adjusted EPS is calculated by dividing adjusted net income by adjusted weighted average shares. The per share impact of Non-GAAP adjustments to arrive at Adjusted EPS is calculated by dividing the dollar amount of the respective Non-GAAP adjustment by adjusted weighted average shares.
- (6) The weighted average shares used to calculate diluted EPS in accordance with GAAP includes dilution, when applicable, resulting from the potential conversion of our 2028 Convertible Notes and 2030 Convertible Notes (collectively, the "Convertible Notes"). In connection with the issuance of the Convertible Notes, we entered into capped call contracts which are expected to reduce the potential dilution on our common stock in connection with any conversion of the Convertible Notes, subject to a cap. Adjusted weighted average shares consists of GAAP weighted average shares used to calculate diluted EPS, including, when applicable, dilutive common stock equivalents that were excluded from weighted average shares used to calculate diluted EPS as their inclusion would be anti-dilutive and excluding, when applicable, dilution resulting from the potential conversion of our Convertible Notes expected to be offset by the capped call contracts.
- (7) Earnings before interest, taxes, depreciation and amortization ("EBITDA") is calculated by adding back interest expense, provision for income taxes, depreciation expense, and amortization expense from intangible assets and financing leases, to income (loss) from continuing operations, which is the most directly comparable GAAP measure.
- (8) Adjusted EBITDA consists of EBITDA plus stock-based compensation, certain legal expenses, restructuring and restructuring-related charges, acquisition and integration costs, other general expenses, ERP implementation, (gain) loss on equity investments, debt conversion inducement expense, European Union medical device regulation incremental charges, other adjustments, and inventory step-up amortization.
- (9) Adjusted Interest Expense on Borrowings is defined as GAAP interest expense on borrowings, which includes only interest expense resulting from our debt facilities, less loss on extinguishment of debt. Adjusted Total Interest Expense is defined as GAAP total interest expense less loss on extinguishment of debt, and is calculated by adding back GAAP Other interest expense to Adjusted Interest Expense on Borrowings.

Adjusted effective interest rate on borrowings is calculated by subtracting from the effective interest rate on borrowings the impact of losses on extinguishment of debt, expressed as a percentage.

- (10) Adjusted Effective Tax Rate is calculated by adding or subtracting from the effective tax rate from continuing operations the impact of Non-GAAP adjustments, expressed as a percentage, to arrive at Adjusted Net Income.
- (11) Free Cash Flow is defined as Net cash provided by operating activities (as stated in our Statement of Cash Flows) reduced by capital expenditures (acquisition of property, plant, and equipment (PP&E), net of proceeds from sale of PP&E).
- (12) Organic Sales Change is reported sales growth adjusted to remove the impact of foreign currency, acquisitions and strategic exits. To calculate the impact of foreign currency on sales growth rates, we convert any sale made in a foreign currency by converting current period sales into prior period sales using the exchange rate in effect at that time and then compare the two, negating any effect foreign currency had on our transactional revenue. For acquisitions, we exclude the impact on the growth rate attributable to the contribution of acquisitions in all periods where there were no comparable sales. For strategic exits, for all periods presented we exclude the impact on the growth rate attributable to sales from the market being exited.

These non-GAAP financial measures exclude the following items, as applicable, for the relevant time periods as indicated in the accompanying non-GAAP reconciliations to the comparable GAAP financial measures:

- Depreciation expense, Amortization expense from intangible assets and Amortization expense from financing leases.
- Certain legal expenses associated with non-ordinary course legal matters.
- Restructuring and restructuring-related charges relate to discrete restructuring programs we initiate primarily to realign resources to better serve our customers and markets, improve operational efficiency and capabilities, and lower operating costs or improve profitability. Depending on the program, restructuring charges may include termination benefits, contract termination, facility closure and other exit and disposal costs. Restructuring-related expenses are directly related to the program and may include retention bonuses, accelerated depreciation, consulting expense and costs to transfer manufacturing operations among our facilities.
- Acquisition and integration costs are incremental costs that are directly related to a business or asset acquisition. These costs may include, among other things, professional, consulting and other fees, system integration costs, and fair value adjustments relating to contingent consideration. We acquired Connemara Biomedical Holdings Teoranta, including its operating subsidiaries Aran Biomedical and Proxy Biomedical (collectively "Aran") in April 2022, InNeuroCo, Inc. in October 2023, Pulse Technologies in January 2024, Precision Coating in January 2025, VSi Parylene in February 2025 and Biocoat Incorporated in December 2025.
- Other general expenses includes gains and losses in connection with the disposal of property, plant and equipment, and discrete transactions occurring sporadically that affect period-over-period comparisons. The third and fourth quarters of 2025 include \$6.2 million and \$0.7 million, respectively, related to termination benefits from actions to align labor with manufacturing volumes. The second quarter of 2024 includes \$1.2 million of loss recoveries relating to property damage which occurred in the fourth quarter of 2023 at one of our manufacturing facilities. The fourth quarter of 2023 amount includes \$2.0 million of property loss and related expenses resulting from that event.
- ERP implementation represents direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance.
- Incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses.
- The accounting associated with our acquisitions require us to record inventory at its fair value, which is sometimes greater than the previous book value of inventory. The increase in inventory value is amortized to cost of sales over the period that the related inventory is sold. We exclude inventory step-up amortization from our non-GAAP financial measures because it is a non-cash expense that we do not believe is indicative of our ongoing operating results.
- Gains and losses on equity investments are generally unpredictable in nature. We do not consider owning equity interests to be a core part of our business strategy. As such, we exclude unrealized and realized gains and losses on our equity investments from our Non-GAAP financial measures, as we do not believe that these components of income or expense have a direct correlation to our ongoing or future core business operations. The third quarter of 2024 includes an impairment charge of \$0.3 million and the third and fourth quarters of 2023 include impairment charges of \$3.3 million and \$2.0 million, respectively, related to investments in two of our non-marketable equity securities.
- Loss on extinguishment of debt consists of accelerated write-offs of unamortized deferred debt issuance costs and discounts which are included in interest expense. Charges in 2025 relate to prepayments made on our TLA Facility. Charges in 2023 include a write off of \$4.4 million of unamortized discount and deferred debt issuance costs in connection with an amendment to our credit agreement, prepayments of portions of our TLA Facility, and full repayment of our TLB Facility.
- Debt conversion inducement expense relates to the partial exchange of our 2028 Convertible Notes and is recorded within Other loss, net in the Condensed Consolidated Statements of Operations for the first quarter of 2025.

- Other adjustments include costs which impact period-to-period comparability and do not represent the underlying ongoing results of our business. For the 2025 and 2023 periods, amounts relate to costs associated with leadership transitions and certain formal strategic projects. Leadership transition costs primarily include severance costs associated with the departure of executives and incremental costs associated with the related leadership transitions. Strategic projects primarily involve system reconfiguration to support our manufacturing excellence operational strategic imperative and investments in certain technology and platform development to align our capabilities to meet customer needs. For 2024, fourth quarter amount includes pre-tax charges for inventory write-offs related to an insolvent customer.

Other adjustments includes the following expenses (in millions):

	2023				2024				2025			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Leadership transition costs	\$ -	\$ 0.9	\$ 0.3	\$ 0.5	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 0.7	\$ 1.0	\$ 2.4
Strategic projects	-	-	1.1	0.7	0.5	0.2	0.3	0.4	0.3	0.3	1.5	0.5
Inventory write-offs	-	-	-	-	-	-	-	1.8	-	-	-	-

- Certain tax items that may be non-recurring, unusual, infrequent and directly related to an event that is distinct and non-reflective of the Company's normal business operations. These may include such items as the retroactive impact of significant changes in tax laws, including changes to statutory tax rates and one-time tax charges. The first quarter of 2025 includes a \$4.1 million write off of a deferred tax asset related to a portion of the unamortized original issue discount due to the partial exchange of the 2028 Convertible Notes. The fourth quarter of 2025 includes a tax benefit of \$3.9 million, related to the finalization of the Company's tax position during the fourth quarter of 2025 and ultimate deductibility of a deferred tax asset that was written off in the first quarter of 2025, and \$4.7 million, related to the release of uncertain tax benefits and interest related to acquired foreign tax credits for which the establishment of the uncertain tax benefit was previously adjusted in prior years.
- The impact of foreign currency and acquisitions on the period presented.
- The income tax provision (benefit) related to these adjustments, based on the estimated tax impact related to the respective adjustment. Tax amounts are computed using a 21% U.S. tax rate, and the statutory tax rates applicable in foreign tax jurisdictions, as adjusted for the existence of net operating losses. Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.